Iveric Bio’s intravitreal solution to treat GA gains FDA approval
A statistically significant reduction in the rate of GA progression at 12 months was demonstrated across the two studies.
07 August 2023
07 August 2023
A statistically significant reduction in the rate of GA progression at 12 months was demonstrated across the two studies.
This decision follows an FDA response to Mesoblast’s BLA resubmission for remestemcel-L.
According to Phase III trial data, Arexvy has 82.6% efficacy in preventing RSV-related LRTD in older people.
Hipra’s Bimervax targets the alpha and beta viral variants, but the EMA recently said it seeks vaccines designed against XBB 1.5 Omicron.
The key focus of the centre will be on pathogens for which there exist no vaccines or for which vaccines are not regulated in the country.
Evox and the Icahn School of Medicine will develop gene delivery vectors for cardiomyocytes for heart disease treatments.
We will be launching our new event Clinical Trials In Rare Diseases Conference 2023 at Princeton Marriott at Forrestal, New Jersey, USA on 13th-14th September! Bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions and much more. With over 40 solution providers this will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.